Anti-sclerostin antibodies: a new frontier in fragility fractures treatment
Bone fragility is the determinant of the increased risk of minimal trauma fracture and must be treated with a multimodal approach that includes pharmacological therapy, physical exercise, and adequate nutrition. Pharmacological therapy, to date based on the administration of antiresorptive drugs, su...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publishing
2023-09-01
|
| Reeks: | Therapeutic Advances in Musculoskeletal Disease |
| Online toegang: | https://doi.org/10.1177/1759720X231197094 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|